MX361160B - Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (pde-10). - Google Patents
Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (pde-10).Info
- Publication number
- MX361160B MX361160B MX2015009627A MX2015009627A MX361160B MX 361160 B MX361160 B MX 361160B MX 2015009627 A MX2015009627 A MX 2015009627A MX 2015009627 A MX2015009627 A MX 2015009627A MX 361160 B MX361160 B MX 361160B
- Authority
- MX
- Mexico
- Prior art keywords
- pde
- inhibitors
- phosphodiesterase
- pyrimidine derivatives
- new pyrimidine
- Prior art date
Links
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title abstract 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title abstract 2
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201330082A ES2480341B1 (es) | 2013-01-24 | 2013-01-24 | Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10) |
| PCT/EP2014/051290 WO2014114695A1 (en) | 2013-01-24 | 2014-01-23 | New pyrimidine derivatives as phosphodiesterase 10 inhibitors (pde-10) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015009627A MX2015009627A (es) | 2016-04-25 |
| MX361160B true MX361160B (es) | 2018-11-28 |
Family
ID=50071592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015009627A MX361160B (es) | 2013-01-24 | 2014-01-23 | Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (pde-10). |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9447095B2 (enExample) |
| EP (1) | EP2948443B1 (enExample) |
| JP (1) | JP6254194B2 (enExample) |
| KR (1) | KR101869144B1 (enExample) |
| CN (1) | CN105008346B (enExample) |
| AU (1) | AU2014209950B2 (enExample) |
| BR (1) | BR112015017678B1 (enExample) |
| CA (1) | CA2897260C (enExample) |
| CY (1) | CY1118552T1 (enExample) |
| DK (1) | DK2948443T3 (enExample) |
| EA (1) | EA026330B1 (enExample) |
| ES (2) | ES2480341B1 (enExample) |
| HR (1) | HRP20161495T1 (enExample) |
| HU (1) | HUE031831T2 (enExample) |
| LT (1) | LT2948443T (enExample) |
| ME (1) | ME02551B (enExample) |
| MX (1) | MX361160B (enExample) |
| PL (1) | PL2948443T3 (enExample) |
| PT (1) | PT2948443T (enExample) |
| RS (1) | RS55449B1 (enExample) |
| SI (1) | SI2948443T1 (enExample) |
| SM (1) | SMT201600428B (enExample) |
| WO (1) | WO2014114695A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017133657A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
| CN107286146B (zh) * | 2017-07-05 | 2020-07-31 | 上海肇钰医药科技有限公司 | 作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途 |
| CN116836162B (zh) * | 2023-05-24 | 2025-09-05 | 南方医科大学 | 吡唑[4,3-c]吡啶类化合物或其药学上可接受的盐及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080221103A1 (en) | 2007-03-09 | 2008-09-11 | Orchid Research Laboratories Ltd. | New heterocyclic compounds |
| SI2617420T1 (sl) | 2009-05-07 | 2016-02-29 | Forum Pharmaceuticals Inc. | Fenoksimetil heterociklične spojine |
| WO2010138430A1 (en) | 2009-05-27 | 2010-12-02 | Merck Sharp & Dohme Corp. | Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors |
| US20120082354A1 (en) | 2009-06-24 | 2012-04-05 | Koninklijke Philips Electronics N.V. | Establishing a contour of a structure based on image information |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| NZ601967A (en) | 2010-03-12 | 2015-03-27 | Omeros Corp | Pde10 inhibitors and related compositions and methods |
| US9284301B2 (en) | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| ES2365960B1 (es) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| WO2011150156A2 (en) | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| US8592423B2 (en) | 2011-06-21 | 2013-11-26 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| US9365562B2 (en) | 2011-10-06 | 2016-06-14 | Merck Sharp & Dohme Corp. | 1,3 substituted azetidine PDE10 inhibitors |
-
2013
- 2013-01-24 ES ES201330082A patent/ES2480341B1/es not_active Expired - Fee Related
-
2014
- 2014-01-23 EA EA201591369A patent/EA026330B1/ru not_active IP Right Cessation
- 2014-01-23 LT LTEP14703553.9T patent/LT2948443T/lt unknown
- 2014-01-23 HU HUE14703553A patent/HUE031831T2/en unknown
- 2014-01-23 HR HRP20161495TT patent/HRP20161495T1/hr unknown
- 2014-01-23 RS RS20160971A patent/RS55449B1/sr unknown
- 2014-01-23 CN CN201480006098.XA patent/CN105008346B/zh active Active
- 2014-01-23 ES ES14703553.9T patent/ES2611170T3/es active Active
- 2014-01-23 JP JP2015554139A patent/JP6254194B2/ja active Active
- 2014-01-23 MX MX2015009627A patent/MX361160B/es active IP Right Grant
- 2014-01-23 CA CA2897260A patent/CA2897260C/en active Active
- 2014-01-23 PL PL14703553T patent/PL2948443T3/pl unknown
- 2014-01-23 BR BR112015017678-0A patent/BR112015017678B1/pt active IP Right Grant
- 2014-01-23 AU AU2014209950A patent/AU2014209950B2/en active Active
- 2014-01-23 EP EP14703553.9A patent/EP2948443B1/en active Active
- 2014-01-23 PT PT147035539T patent/PT2948443T/pt unknown
- 2014-01-23 DK DK14703553.9T patent/DK2948443T3/en active
- 2014-01-23 WO PCT/EP2014/051290 patent/WO2014114695A1/en not_active Ceased
- 2014-01-23 KR KR1020157022767A patent/KR101869144B1/ko active Active
- 2014-01-23 ME MEP-2016-254A patent/ME02551B/me unknown
- 2014-01-23 SI SI201430093A patent/SI2948443T1/sl unknown
- 2014-01-24 US US14/762,655 patent/US9447095B2/en active Active
-
2016
- 2016-11-23 CY CY20161101206T patent/CY1118552T1/el unknown
- 2016-11-23 SM SM201600428T patent/SMT201600428B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015028501B8 (pt) | Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| CA2875877C (en) | Syk inhibitors | |
| MX377552B (es) | Proceso para preparar un compuesto antiviral de formula i. | |
| BR112015021701A2 (pt) | novos compostos inibidores da fosfoestearase tipo 10a | |
| PH12013501199A1 (en) | Photochromic compounds and compositions | |
| EA201691625A1 (ru) | Ароматические гетероциклические соединения как противовоспалительные соединения | |
| MY165730A (en) | Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof | |
| GEP20146169B (en) | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors | |
| MX2014002442A (es) | Inhibidores de pirrolopirazina cinasa. | |
| BR112015028452A2 (pt) | agonistas do receptor somastatina subtipo 4 (sstr4) | |
| PH12012501692A1 (en) | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions | |
| PH12013501941A1 (en) | Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors | |
| PH12015502047A1 (en) | Novel pyrimidine and pyridine compounds and their usage | |
| PH12015500211B1 (en) | 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | |
| BR112015026721A2 (pt) | derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer | |
| MX368781B (es) | Compuesto inhibidor de las actividades de las cinasas btk y/o jak3. | |
| MX368882B (es) | Proceso para la preparacion de triazinas. | |
| PL401473A1 (pl) | Nowe, silnie fluorescencyjne substancje heterocykliczne i sposób ich otrzymywania | |
| PH12016500735A1 (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| IN2014DN05972A (enExample) | ||
| MX2015009627A (es) | Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (pde-10). | |
| MX2015003419A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a. | |
| SG10201901578UA (en) | Processes for the preparation of pyrimidinylcyclopentane compounds | |
| IN2014KN00847A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |